Open AccessPazopanib diminishes non‐small cell lung cancer ( NSCLC ) growth and metastases in vivo
Author(s) -
Zhao Honglin,
Yang Fan,
Shen Wang,
Wang Yuli,
Li Xuebing,
You Jiacong,
Zhou Qinghua
Publication year - 2015
Publication title -
thoracic cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.823
H-Index - 28
eISSN - 1759-7714
pISSN - 1759-7706
DOI - 10.1111/1759-7714.12138
Subject(s) - pazopanib , medicine , angiogenesis , cancer research , in vivo , lung cancer , cell growth , cancer , pharmacology , oncology , biology , sunitinib , microbiology and biotechnology , genetics
Background Anti‐angiogenesis has been demonstrated to have a critical role in lung cancer pathogenesis. Here, we characterized the effect of the small‐molecule angiogenesis inhibitor pazopanib on non‐small cell lung cancer ( NSCLC ) cells. Methods NSCLC cells were tested for viability and migration after incubation with varying concentrations of pazopanib. Further, the phosphorylation status of extracellular signal‐regulated kinase, protein kinase B, and MEK were assessed in vitro. For in vivo testing, mice grafted with NSCLC cell lines L9981 and A549 were treated orally with pazopanib. Results Pazopanib inhibits signaling pathways in tumor cells, thus blocking NSCLC cell growth and migration in vitro and inducing tumor cell arrest at G0 / G1 phase. We show that pazopanib could inhibit tumor cell growth, decrease metastases, and prolong survival in two mouse xenograft models of human NSCLC . Conclusion These preclinical studies of pazopanib show the possibility of clinical application and, ultimately, improvement in patient outcome.